Figure 4. Quantification of BrdU positive cells co-labeled with either GFAP or Foxj1-tdT, or both in different regions of the lesion at 2 weeks after SCI.

(a) Schematic of 5 dorso-ventral levels quantified and graphs showing the total number of cells per tissue volume and mean percent of BrdU labeled cells that are co-labeled with GFAP or Foxj1-tdT or both across the entire astrocyte scar (AS). Total values were derived by averaging counts from 6 boxes across the entire transverse spinal cord at each of the 5 levels as shown in (b,c). (b) Schematic of 6 counting boxes evaluated across the transverse spinal cord at dorsal and ventral levels D₂ and V₂. Graphs show the mean number of cells per volume and mean percent of BrdU labeled cells that are co-labeled with GFAP or Foxj1-tdT or both across the entire transverse plane, as well number or percent of cells per box. (c) Schematic of 6 counting boxes evaluated across the transverse spinal cord at the middle (M) level of the ependymal layer (Ep). Graphs show the mean number of cells per volume and mean percent of BrdU labeled cells that are co-labeled with GFAP or Foxj1-tdT or both across the entire transverse plane, as well number or percent of cells per box. (d) Schematic of lesion core (LC) at the middle (M) level containing the ependymal layer (Ep). Graphs show the total number per volume of BrdU labeled cells that are co-labeled with GFAP or Foxj1-tdT or both across the entire transverse plane, as well the percent of such cells in the entire SCI lesion that are located in either the lesion core or astrocyte scar. n = 6 per group, *p < 0.001 versus GFAP + BrdU only (ANOVA with Newman-Keuls), ^p < 0.001 (t-test).